John Byon

741 total citations
17 papers, 600 citations indexed

About

John Byon is a scholar working on Molecular Biology, Immunology and Hematology. According to data from OpenAlex, John Byon has authored 17 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Immunology and 6 papers in Hematology. Recurrent topics in John Byon's work include Protein Tyrosine Phosphatases (5 papers), Acute Myeloid Leukemia Research (3 papers) and Virus-based gene therapy research (3 papers). John Byon is often cited by papers focused on Protein Tyrosine Phosphatases (5 papers), Acute Myeloid Leukemia Research (3 papers) and Virus-based gene therapy research (3 papers). John Byon collaborates with scholars based in United States, Switzerland and Singapore. John Byon's co-authors include Anasua B. Kusari, Jyotirmoy Kusari, Kathleen A. Kenner, Thalia Papayannopoulou, Safiyyah Ziyad, Michelle Blake, William Bensinger, Myo Htut, Julia Piasecki and Andrzej Jakubowiak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

John Byon

17 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Byon United States	12	442	177	152	94	87	17	600
Shuangwei Li United States	12	535 1.2×	230 1.3×	194 1.3×	27 0.3×	76 0.9×	17	704
Merav Yoeli-Lerner United States	7	637 1.4×	104 0.6×	182 1.2×	26 0.3×	125 1.4×	7	814
Sylvie Rodrigues France	11	436 1.0×	231 1.3×	224 1.5×	42 0.4×	98 1.1×	11	801
Anita L. Korapati United States	5	418 0.9×	128 0.7×	258 1.7×	30 0.3×	79 0.9×	6	638
Madhavi Bathina United States	8	597 1.4×	107 0.6×	183 1.2×	84 0.9×	102 1.2×	10	771
Christine Teixeira Canada	8	581 1.3×	253 1.4×	301 2.0×	18 0.2×	126 1.4×	9	939
Babette Aicher Germany	11	423 1.0×	79 0.4×	105 0.7×	23 0.2×	52 0.6×	28	607
Chao-Pei Betty Chang United States	9	537 1.2×	70 0.4×	124 0.8×	25 0.3×	86 1.0×	13	847
Ana M. Cosialls Spain	18	601 1.4×	129 0.7×	255 1.7×	70 0.7×	99 1.1×	29	842

Countries citing papers authored by John Byon

Since Specialization

Citations

This map shows the geographic impact of John Byon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Byon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Byon more than expected).

Fields of papers citing papers by John Byon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Byon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Byon. The network helps show where John Byon may publish in the future.

Co-authorship network of co-authors of John Byon

This figure shows the co-authorship network connecting the top 25 collaborators of John Byon. A scholar is included among the top collaborators of John Byon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Byon. John Byon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Li, Daneng, et al.. (2024). Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2687–TPS2687. 2 indexed citations

Li, Daneng, Anthony F. Shields, Hirva Mamdani, et al.. (2024). Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.. Journal of Clinical Oncology. 42(3_suppl). 749–749. 1 indexed citations

Mailankody, Sham, Myo Htut, Kelvin P. Lee, et al.. (2018). JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE). Blood. 132(Supplement 1). 957–957. 88 indexed citations

Yan, Mark, Judy Zhong, Kartik Krishnan, et al.. (2017). Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents. Blood. 130. 4241–4241. 1 indexed citations

Yadav, Mahesh, Cherie Green, Rin Nakamura, et al.. (2016). Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma. Blood. 128(22). 2102–2102. 14 indexed citations

Dail, Monique, Long Yang, Edward E. Kadel, et al.. (2016). Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML. Blood. 128(22). 1340–1340. 12 indexed citations

Till, Brian G., Steven I. Park, Leslie Popplewell, et al.. (2015). Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 126(23). 5104–5104. 14 indexed citations

Yeung, Cecilia C.S., John Byon, Aravind Ramakrishnan, et al.. (2014). The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy. PLoS ONE. 9(9). e107817–e107817. 23 indexed citations

Byon, John, et al.. (2014). Deletion of Dicer in late erythroid cells results in impaired stress erythropoiesis in mice. Experimental Hematology. 42(10). 852–856.e1. 8 indexed citations

10.

Byon, John, Jing Chen, Raymond T. Doty, & Janis L. Abkowitz. (2013). FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function. Blood. 122(16). 2903–2910. 12 indexed citations

11.

Li, Xiang, Feng Xu, Chunkang Chang, et al.. (2012). Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. 98(3). 414–419. 43 indexed citations

12.

Byon, John & Thalia Papayannopoulou. (2011). MicroRNAs: Allies or Foes in erythropoiesis?. Journal of Cellular Physiology. 227(1). 7–13. 30 indexed citations

13.

Byon, John, Shrikrishna Dadke, Samuel Rulli, Anasua B. Kusari, & Jyotirmoy Kusari. (2001). Insulin regulates MAP kinase phosphatase-1 induction in Hirc B cells via activation of both extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK). Molecular and Cellular Biochemistry. 218(1-2). 131–138. 14 indexed citations

14.

Kusari, Anasua B., John Byon, & Jyotirmoy Kusari. (2000). Substitution of two insulin receptor carboxy-terminal tyrosines with phenylalanine impairs the expression of MAP kinase phosphatase-1 (MKP-1) mRNA. Molecular and Cellular Biochemistry. 211(1-2). 27–37. 3 indexed citations

15.

Byon, John, Anasua B. Kusari, & Jyotirmoy Kusari. (1998). Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Molecular and Cellular Biochemistry. 182(1-2). 101–108. 247 indexed citations

16.

Byon, John, Kathleen A. Kenner, Anasua B. Kusari, & Jyotirmoy Kusari. (1997). Regulation of Growth Factor-Induced Signaling by Protein-Tyrosine-Phosphatases. Experimental Biology and Medicine. 216(1). 1–20. 41 indexed citations

17.

Kusari, Anasua B., John Byon, Debdutta Bandyopadhyay, Kathleen A. Kenner, & Jyotirmoy Kusari. (1997). Insulin-Induced Mitogen-Activated Protein (MAP) Kinase Phosphatase-1 (MKP-1) Attenuates Insulin-Stimulated MAP Kinase Activity: A Mechanism for the Feedback Inhibition of Insulin Signaling. Molecular Endocrinology. 11(10). 1532–1543. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact